PMID- 32256092
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 13
DP  - 2020
TI  - Antioxidant and Anti-Inflammatory Properties of Melatonin in Patients with Type 2 
      Diabetes Mellitus with Periodontal Disease Under Non-Surgical Periodontal 
      Therapy: A Double-Blind, Placebo-Controlled Trial.
PG  - 753-761
LID - 10.2147/DMSO.S242208 [doi]
AB  - BACKGROUND AND AIM: The imbalance between pro-oxidant and antioxidant systems 
      often leads to further oxidative damage in the pathogenesis of both diabetes and 
      periodontal disease. This study aimed to investigate the antioxidant and 
      anti-inflammatory properties of melatonin in type 2 diabetes mellitus (T2DM) 
      patients with periodontal disease (PD) under non-surgical periodontal therapy 
      (NSPT). MATERIALS AND METHODS: In this double-blind clinical trial study, 50 T2DM 
      patients with PD were randomly allocated to intervention and control groups and 
      received 250 mg/day (2 tablets) either melatonin or placebo 1 h before bedtime 
      for 8 weeks. The NSPT was performed for all patients in both groups at the 
      beginning of the study. The serum levels of interleukin-1b (IL-1b), 
      malondialdehyde (MDA), total antioxidant capacity (TAC), superoxide dismutase 
      (SOD), catalase (CAT), and glutathione peroxidase (GPx) were measured pre- and 
      post-intervention. RESULTS: Supplementation with melatonin in adjunct to NSPT 
      significantly increased the serum levels of TAC, SOD, CAT, and GPx in the 
      intervention group (P = 0.02, 0.008, 0.004 and 0.004, respectively). The mean 
      changes of SOD, CAT, and GPx were significantly (P = 0.02, 0.04 and 0.04, 
      respectively) greater in the intervention group compared with the control group. 
      Also, after adjusting for confounding factors, the results did not change in 
      terms of significance (P < 0.05). After the intervention, serum levels of MDA and 
      IL-1b were significantly reduced in the intervention group (P < 0.001 and P = 
      0.008, respectively). The intervention group exhibited lower mean changes of MDA 
      compared with the control group, and these changes were statistically significant 
      (P = 0.008). In addition, after adjusting for confounding factors, the results 
      did not change in terms of significance. CONCLUSION: The adjunctive effects of 
      melatonin and NSPT may improve inflammatory and antioxidant parameters in T2DM 
      patients with PD.
CI  - (c) 2020 Zare Javid et al.
FAU - Zare Javid, Ahmad
AU  - Zare Javid A
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
AD  - Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur 
      University of Medical Sciences, Ahvaz, Iran.
FAU - Hosseini, Seyed Ahmad
AU  - Hosseini SA
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
AD  - Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur 
      University of Medical Sciences, Ahvaz, Iran.
FAU - Gholinezhad, Hassan
AU  - Gholinezhad H
AD  - Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur 
      University of Medical Sciences, Ahvaz, Iran.
FAU - Moradi, Leila
AU  - Moradi L
AD  - Health Research Institute, Diabetes Research Center, Ahvaz Jundishapur University 
      of Medical Sciences, Ahvaz, Iran.
FAU - Haghighi-Zadeh, Mohammad Hosein
AU  - Haghighi-Zadeh MH
AD  - Department of Biostatistics, School of Public Health, Ahvaz Jundishapur 
      University of Medical Sciences, Ahvaz, Iran.
FAU - Bazyar, Hadi
AU  - Bazyar H
AUID- ORCID: 0000-0002-1627-7122
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
AD  - Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, 
      Ahvaz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200318
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC7090208
OTO - NOTNLM
OT  - antioxidant enzymes
OT  - inflammatory markers
OT  - melatonin
OT  - periodontal disease
OT  - type 2 diabetes mellitus
COIS- The authors have declared that they have no conflicts of interest in this work.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
PMCR- 2020/03/18
CRDT- 2020/04/08 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
PHST- 2020/03/18 00:00 [pmc-release]
AID - 242208 [pii]
AID - 10.2147/DMSO.S242208 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2020 Mar 18;13:753-761. doi: 10.2147/DMSO.S242208. 
      eCollection 2020.